hsci: the first russian public biotech company placement...investment objective – development of...
TRANSCRIPT
HSCI: the first Russian public
biotech company
(expanding into new geographic markets)
TEASER for Investor presentation
(road-show for sale of 28.6 % of HSCI’s
increased share capital) June 2014
2
Disclaimer
Certain statements in this presentation are forward-looking statements within the meaning of
the U.S. federal securities laws and are intended to be covered by the safe harbors created thereby.
Those forward-looking statements include, but are not limited to:
• management’s assessment of the Company’s future results, including revenue, net profit(loss), profit(loss) per share,
dividends, investments, capital structure, margins and other operating and financial results;
• forecasts of the present value of future cash flows and related factors;
• the Company’s plans, goals and tasks relating, among other things, to its products and services development;
• the Company’s expectations with respect to improving its corporate governance practices;
• the Company’s market position – as anticipated;
• economic outlook and industry trends;
• the Company’s expectations as to the sector regulation and assessment of impact of regulatory initiatives on the
Company’s activity;
• assumptions and prerequisites under the statements.
Such forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to
differ materially from those expressed or implied by these forward-looking statements.
These risks include the risk of changes in political, economic and social conditions in Russia as well as changes in global
economic environment, the risks relating to changes in industry regulation and the Russian legislation, the risk of changes
in the Company’s operations and business prospects, the competition and other risks.
For a more detailed discussion of these and other factors, see the Company’s Annual Report and other public filings.
Many of these factors are beyond the Company’s ability to control or predict. Given these and other uncertainties, readers
are cautioned not to place undue reliance on any of the forward-looking statements contained herein or otherwise. The
Company does not undertake any obligation to release publicly any revisions to these forward-looking statements (which
are made as of the date hereof) to reflect events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events, except as may be required under applicable laws.
About the Company
Human Stem Cells Institute (HSCI) is Russia’s public biotech company (ticker: ISKJ) founded in 2003.
HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in
the field of advanced biomedical technologies, including such segments as:
• Gene therapy
• Regenerative medicine (stem cell therapy and services, tissue engineering products)
• Medical genetics, including reproductive genetics (Lab & clinics /genetic testing and consulting/)
• Bio-insurance
• Biopharmaceutics (within the international SуnBio project)
3
Gemabank – a family cord blood stem cell bank, the largest in Russia and the CIS, as well as Reprobank, a reproductive cell and tissue bank
Neovasculgen® – the-first-in-class gene-therapy drug for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI)
SPRS-therapy – a set of personalized diagnostics and treateatment procedures based on the innovative cell technology which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes
Genetico medical genetics centers that provide genetic diagnostics and consulting services
The Company’s key products include:
HSCI Medical
genetics
Bio-insurance
Drug
development
HSCI Group Projects (as of June 2014)
2003 2013
2009 (IPO)
Products on the market 1
Revenue, IFRS (RUB mln) 146
Market Cap (RUB mln) ≈ 750
2013
7
420
≈ 1,440
HSCI is a multifaceted biotech
company having a diversified revenue
and targeting on business expansion,
entering new geographic markets and
increasing shareholder value
10 Years’ History: Achievements
5
Mono-brand (Gemabank, projects in the field of cell technologies)
IPO Change of status, competencies development, PR + IR
Multi-brand International status
CAGR = 35%
• HSCI has a high-growth business: annual revenue
growth averaged 35% in 2008-2013
• Business model is diversified as the company has
several business lines that generate revenue
• Business is financially stable. Net debt / OIBDA was
0.47 (as of Dec. 31, 2013)
Key Financials (Under IFRS)
6
50%
46%
4%
2013
80%
11%
9%
2012
100%
2004-2010
Revenue breakdown (under IFRS)
97
146
193
262 300
420
0
50
100
150
200
250
300
350
400
450
2008 2009 2010 2011 2012 2013
Revenue Dynamics in RUB mln
In RUB million 2013
Revenue 419.77
Operating expenses, incl. 377.11
Depreciation & amortization 22.5
OIBDA 65.17
Operating profit 42.66
Net profit 16.67
Total comprehensive income 16.73
OIBDA margin, % 15.5%
Operating margin, % 10.2%
Net profit margin, % 4.0%
Net debt 30.36
Net debt / OIBDA 0.47
Gemabank
New products & services
(Neovasculgen, Genetic testing & consulting, SPRS-therapy)
Other revenue
Business model - 2014
7
Gemabank – business that has been
generating revenue in Russia for over
10 years
New products in the Russian market,
business diversification
Scaling the Business
(bringing existing products and services to new geographic markets)
R&D (product candidates
pipeline)
HSCI Strategy: innovative products and creation продукты
of new markets -- > having gained a majority
share, grow with the market
Sale of
licenses
IP Creation
Medical genetics
consulting
Taking advantage of the company’s strengths, expertise, and competencies for
scaling the business into new geographic markets
International Markets Entry
Growing cash flow from products and services launched in Russia
Experienced team of professionals
Medical and scientific competencies
Experience of developing innovative products and services, obtaining regulatory approvals, and launching such products and services in the markets
IP-protection
Strong proprietary R&D base
Established sales channels
Focus on high growth market segments
Financial investments in foreign companies of the sector
Scaling into new geographic markets
8
Neovasculgen®: development, FDA clearance, and launch in the USA and China
Investments: Pre-clinical and clinical trials (Phase I, II in the USA (~ 3 years) – $ 20 mln
Development of services in the field of regenerative medicine and medical genetics
in Europe
Starting from 2014:
Road show -> private placement/SPO of 28.6% of increased share capital
(additional issue of 30 mln shares)
Some Parameters of the Investment Program
9
Main goal – scaling the business into new geographic markets
Investment objective – development of HSCI’s products and services outside of Russia:
• Pre-clinical studies and clinical trials of Neovasculgen® gene therapy drug in the USA
• Pre-clinical studies and clinical trials of Neovasculgen® gene therapy drug in China
• Purchase of stakes in European regenerative medicine companies (cord blood banks, etc.)
• Launch of genetic diagnostic services in Europe
• Launch of cell-based services in Europe
In addition:
• Genetico project (jointly with RVC BioFund) – development of a chain of Genetico medical centers to provide a range of personalized genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders
Amount (in RUB mln)
2014-2016 2017-2020
TOTAL
up to 600 up to 2,700
HSCI: Investment Case
• Proven business model. Sales history from 2003.
• Focused business model of personalized medicine of the future – knowledge about genetics for diagnosing, preventing and treating diseases, regenerative medicine, and bio-insurance.
• Innovative products and services help the Company to create new markets to capitalize on growth opportunities which they present while gaining market lidership.
• Business transparency – IFRS financial statements audited by Ernst & Young.
• Investment history and investor relations experience. The Company’s shares have been publicly traded on the MICEX since 2009 (ticker – ISKJ).
• Professional management team capable of managing business in a period of high growth.
• Scaling the business into international markets should create a platform for sustainable growth in the long term.
According to the Company estimations, HSCI’s shares may trade with an 180% upside. (current price per HSCI’s ordinary share on the MICEX is RUB 15 as of 11.06.2014; target price is RUB 40-50 in 2.5 - 3 years).
Investor exit strategy may include RTO (reverse takeover) and / or listing on a stock exchange outside of Russia in 2.5 - 3 years (e.g. in the US).
Global markets have high-growth rates averaging 25% - 30% and more:
Global gene therapy market with Neovasculgen® taken into account – over US$ 2 billion by 2025; Global regenerative medicine market is forecast to grow from US$ 1 billion in 2011 up to US$ 5 billion by 2017; Global market of stem cell therapeutics may grow from US$ 855 million in 2015 up to US$ 9 billion by 2020.
10
HSCI: Investment Profile
IPO (December 2009)
HSCI OJSC placed 15 million ordinary shares
(20% of the increased shart capital)
Offering price – RUB 9.5 per share
Amount raised – RUB 142.5 million (USD 4.8 billion)
Over 300 new shareholders at the IPO
Traded on
MICEX (ticker: ISKJ) – iIM (Innovation & Investment Market)
Today MICEX is part of the Moscow Exchange (MOEX)
Recent stock price 11.06.2014: RUB 15.00; MCap – RUB 1,1 bln (USD 32,7 mln)
52 WK HI/LO: RUB 12.70 / 21.99
Free float
≈ 20% ORD (of the 75 million ord shares outstanding)
Number of shareholders
As of May 6, 2014: 1,101
Dividend policy
As recommended by the BoD
2009: 32% of net profit under RAS for 2009;
2010 - 2012: no dividend payments;
2013: pay 98% of net profit under RAS for 2013
(AGM to decide on June 17, 2014) 11
Ownership structure as of May 6, 2014
(the record day for the AGM)
For more information, please refer to: http://eng.hsci.ru/investoram-i-aktsioneram/share-capital-stock-market/shareholder-structure
HSCI vs MICEX Index: 10.06.2011 – 11.06.2014
16.80%
3.12%
32.15% 24.00%
4.01%
19.92% Artur Isaev, HSCI's CEO
HSCI's BoD members and employees
First International Investment Group Ltd.
Dynamic Solutions Ltd.*
NextGene LLC**
Other (mostly Russian individualshareholders)
* Change in HSCI's shareholding structure as of December 27, 2013 - see: Press-release
(January 14,2014)
** Treasury shares of HSCI, which occurred due to the mandatory buy-back in 2011 (4.67%
of HSCI’s share capital), were realized during the year 2012 as required by law, with the part
of them (in the amount of 4.01% of HSCI’s share capital) having been brought to the charter
capital of HSCI’s 100% subsidiary NextGen LLC as an additional contribution.
Contacts
Mailing address: P.O. box 373, Bld. 2, 3 Gubkina Str., Moscow 119333, Russia Legal Address: 18/1 Olimpiysky prospect, Moscow 129110, Russia Phone/(Fax): +7(495) 646-80-76 Chief Executive Officer:
Artur Isaev Tel.: +7(495) 646-8076 E-mail: [email protected]
Investor Relations Director:
Svetlana Samoylova Tel.: +7(495) 646-8076, ext.180
+7 (963) 679 35 08 E-mail: [email protected]
Analyst:
Dmitry Krasotkin Mob.: +7(916) 657 38 74, E-mail: [email protected]
12
Website:
www.hsci.ru
Social networks:
Twitter Facebook YouTube LinkedIn